Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23764025 | 0.92 | LMNA (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL6095146 | 0.90 | CYP3A4 (0.42) | P2RX4GRIN2BALDH1A1CYP3A4 | |
| SCHEMBL20635282 | 0.87 | CYP2D6 (0.46) | TDP1CYP3A4 | |
| SCHEMBL432657 | 0.85 | KMT2A (0.49) | P2RX4GRIN2BTDP1NPC1RAB9A | |
| SCHEMBL26597537 | 0.84 | TBXAS1 (0.52) | NPC1RAB9AALDH1A1CYP3A4HPGD | |
| SCHEMBL15435863 | 0.84 | CYP19A1 (0.49) | FAAHMGLL | |
| SCHEMBL12016623 | 0.84 | ALDH1A1 (0.39) | TDP1ALDH1A1 | |
| SCHEMBL6101374 | 0.84 | QPCT (0.42) | HCAR2CYP3A4FAAHMGLL | |
| SCHEMBL19973625 | 0.83 | CA12 (0.50) | NPC1RAB9AALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL12964049 | 0.82 | FAAH (0.45) | ALDH1A1CYP3A4HPGDTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114787139-B | Methods and intermediates for preparing MCL1 inhibitors | 吉利德科学公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114787139-A | Processes and intermediates for preparing MCL1 inhibitors | 吉利德科学公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20060094880-A9 | Synthetic process for trans-aminocyclohexyl ether compounds | BARRETT ANTHONY G M | 2006-05-04 | — | — | US | disclosed |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094880-A9 | Synthetic process for trans-aminocyclohexyl ether compounds | AKR1C3, CBR1, CBR3 | P2RX4 4721/4885GRIN2B 2196/4885HCAR2 185/4885 |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | AKR1C3, CBR1, CBR3 | P2RX4 4721/4885GRIN2B 2196/4885HCAR2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.